All In Biotech

Drug Trial Radar · NCT04647435

Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction

National, Multicentre, Randomized, Double-blind, Triple-dummy Active-Controled Phase III Clinical Trial to Evaluate the Efficacy and Safety of APSCTC for the Treatment of Postsurgical Pain Due to Third Molar Extraction.

Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

396

Actual

Start

May 13, 2023

Primary completion

Oct 4, 2024

Study completion Oct 4, 2024

Sponsor

Lead sponsor
Apsen Farmaceutica S.A.Industry
Sponsor type
Industry
First posted
Dec 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 40 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy of APSCTC compared to two active drugs in acute pain relief.

Conditions

  • Postsurgical Pain
  • Third Molar Extraction

Interventions

  • APSCTCDrug

    APSCTC + Toragesic® placebo + Tramal® placebo

  • Toragesic®Drug

    APSCTC placebo + Toragesic® + Tramal® placebo

  • Tramal®Drug

    APSCTC placebo + Toragesic® placebo + Tramal®

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. At least 50% of maximum pain relief score (TOTPARmax)Time frame: Change from Baseline to 6 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.

    Valinhos, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.